Structurally altered proteins (derived from chromosomal translocations or gene mutations) can be considered tumor specific antigens and represent an attractive target for a T-cell mediated response. T lymphocytes recognize antigens in the form of peptides bound to HLA-mole-cules.
Materials and methods
Peptides derived from oncogenic proteins were screened fro the presence of HLA binding motifs; actual binding were evaluated by HLA stabilization experiments using transfectants and specific anti-HLA antibodies. Specific lymphocytes were induced by in vitro peptide sensitization and screened by thymidine uptake or cellular cytotoxic assays.
Results
We identified peptides derived from EWS/FLI-1 fusion protein and from mutated K-RAS protein (encompassing respectively the fusion point and the mutation at position 12) that showed binding motif for HLA-Cw*0702 and HLA-A3 respectively. The actual binding of these peptides was analysed in a stabilization assay. We detected binding for the EWS/FLI-I peptide and for 5 RAS peptides (1 wild type and 4 mutated). The effect of temperature, β2-microglobulin (β2-m) and fetal calf serum (FCS) on the binding and the stability of the HLA/peptide complex was studied. A low temperature (26°C) increased the binding both in HLA-A3 and HLA-Cw*0702, while FCS reduced it. β2-m increased the binding to the HLA-A3 molecule but did not influence the binding to the HLA-Cw*0702. The stability of already formed complexed was somewhat different in the HLA-A3 and HLA-Cw*0702 system: both were more stable at 26°C than at 37°C but while the β2-m and FCS did not influence the stability of the HLA-A3/peptide complex, they seemed to cause opposite effects in the HLA-Cw*0702 system (β2-m stabilized and FCS destabilized the complex). Finally, we were able to generate a specific CD8+ CTL line against a K-RAS mutated peptide.
Conclusions
Although binding motifs and actual HLA binding can be detected in several cases, the generation of a cellular response is infrequent, confirming that HLA binding is necessary but not sufficient to obtain an in vitro response. Further optimization of culture conditions, type of Antigen Presenting Cells (APC), peptides, use of stabilizers like β2-m are still needed.
AlmogueraC., ShibataD., ForresterK., MartinJ., ArnheimN., PeruchoM.: Most human carcinomas of the exocrine pancreas contain mutant c-k-ras genes.Cell, 53: 549–554, 1988.
2.
ApplemanL.J., FreyA.B.: Tumor antigens encoded by oncogenes and the impact of oncogenes upon the immune response.Cell. Immunol., 170: 1–10, 1996.
BocchiaM., KorontsvitT., XuQ., MackinnonS., YangS.Y., SetteA., ScheinbergD.A.: Specific human cellular immunity to bcr-abl oncogene-derived peptides.Blood, 87: 3587–3592, 1996.
5.
BosJ.L.: Ras oncogenes in human cancer: a review.Cancer Res., 49: 4682–4689, 1989.
6.
BrusicV., RudyG., HarrisonL.C.: MHCPEP: a database of MHC-binding peptides.Nucleic Acids Research, 22: 3663–3665, 1994.
7.
CelisE., TsaiV., CrimiC., DeMarsR., WentworthP.A., ChesnutR.W., GreyH.M., SetteA., SerraH.M.: Induction of antitumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes.Proc. Natl. Acad. Sci. USA, 91: 2105–2109, 1994.
8.
CernyA., McHutchisonJ.G., PasquinelliC., BrownM.E., BrothersM.A., GrabscheidB., FowlerP., HoughtonM., ChisariF.V.: Cytotoxic T lymphocytes response to hepatitis C virus-derived peptides containing the HLA-A2.1 binding motif.J Clin. Invest., 95: 521–530, 1995.
9.
CerundoloV., ElliottT., ElvinJ., BastinJ., RammenseeH., TownsendA.: The binding affinity and dissociation rates of peptides for class I major hisotcompatibility complex molecules.Eur. J. Immunol., 21: 2069–2075, 1991.
10.
CheeverM.A., DisisM.L., BernhardH., GralowJ.R., HandS.L., HusebyE.S., Lian QinH., TakahashiM., ChenW.: Immunity to oncogenic proteins.Immunol. Rev., 145: 33–59, 1995.
11.
De la SalleH., HanauD., FrickerD., UrlacherA., KellyA., SalameroJ., PowisS.H., DonatoL., BausingerH., LaforetM., JerasM., SpehnerD., BieberT., FalkenrodtA., Caze-naveJ.P., TrowsdaleT., TongioM.M.: Homozygous human TAP peptide transporter mutation in HLA class I deficiency.Science, 265: 237–241, 1994.
12.
DelattreO., ZucmanJ., PlougastelB., DesmazeC., MelotT., PeterM., KovarH., JoubertI., De JongP., RouleauG., AuriasA., ThomasG.: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.Nature (London), 359: 162–165, 1992.
13.
Der-mimeS., BertazzoliC., MarchesiE., RavagnaniF., BlaserK., CorneoG.M., PoglianiG., ParmianiG., Gambacorti-PasseriniC.: Lack of T-cell mediated recognition of the fusion region of the pml/RAR hybrid protein by lymphocytes of acute promyelocytic leukemia patients.Clin. Cane. Res., 2: 593–600, 1996.
14.
DibrinoM., TsuchidaT., TurnerR.V., ParkerK.C., ColiganJ.E., BiddisonW.E.: HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs.J. Immunol., 151: 5930–5935, 1993.
FossumB., OlsenA.C., ThorsbyE., GaudernackG.: CD8+ T cells from a patient with colon carcinoma, specific to a mutant p21-Ras-derived peptide (Gly13 Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation.Cancer Immunol. Immunother., 40: 165–172, 1995.
17.
Gambacorti-PasseriniC.: Immunogenicity of fusion proteins.Int. J. Clin. Lab. Res., 23: 186–191, 1993.
18.
Gambacorti-PasseriniC., BertazzoliC., DermimeS., ScardinoA., SchendelD., ParmianiG.: Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers.Clin. Cane. Res., 3: 676–683, 1997.
19.
Gambacorti-PasseriniC., GrignaniF., ArientiF., PandolfiP.P., PelicciP.G., ParmianiG.: Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR present in acute promyelocytic leukemia cells.Blood, 81: 1369–1375, 1993.
20.
GrecoG., FruciD., AccapezzatoD., BarnabaV., NisiniR., AlimenaG., MontefuscoE., VignetiE., ButlerR., TanigakiN., TosiR.: Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes.Leukemia, 10: 693–699, 1996.
21.
JägerE., RinghofferM., KarbachJ., ArandM., OeschF., KnuthA.: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cy-totoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.Int. J. Cancer, 66: 470–476, 1996.
22.
JureticA., Jürgen-GöbelJ., SchaeferC., NoppenC., WillimannT.E., KocherT., ZuberM., HarderF., HebererM., SpagnoliG.C.: Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage.Int. J. Cancer,68: 471–478, 1996.
23.
KastM.W., BrandtR.M.P., SidneyJ., DrijfhoutJ., KuboR.T., GreyH.M., MeliefC.J.M., SetteA.: Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins.J. Immunol.152: 3904–3912, 1994.
24.
LehmannF., MarchandM., HainautP., PouillartP., SastreX., IkedaH., BoonT., CoulieP.G.: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection.Eur. J. Immunol.25: 340–347, 1995.
25.
McIntyreC.A., ReesR.C., PlattsK.E., CookeC.J., SmithM.O., MulcahyK.A., MurrayA.K.: Identification of peptide epitopes of MAGE-1,-2,-3 that demonstrate HLA-A3-specific binding.Caner. Immunol. Immunother., 42: 246–250, 1996.
26.
OlsenA.C., FossumB., KirkinA.F., ZeuthenJ., GaudernackG.: A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune response.Scand. J. Immunol., 41: 357–364, 1995.
27.
PlebanskiM., AllsoppC.E.M., AidooM., ReyburnH., HillA.V.S.: Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood.Eur. J. Immunol., 25: 1783–1787, 1994.
28.
RabbitsT.H.Chromosomal translocations in human cancer.Nature (London), 372: 143–149, 1994.
29.
RammenseeH., FriedeT., StefanovicS.: MHC ligands and peptide motifs: first listing.Immunogenetics, 41: 178–228, 1995.
RosenbergS.A., KawakamiY., RobbinsP.F., WangR.: Identification of the genes encoding cancer antigens: implications for cancer immunotherapy.Adv. Cancer Research, 70: 146–175, 1997.
32.
SalterR.D., CresswellP.: Impaired assembly and transport of HLA-A and B antigens mutants TxB cell hybrid.Embo J., 5: 943–949, 1986.
33.
ScarpaA., CapelliP., VillanuevaA., ZamboniG., LluisF., AccollaR., MariuzziG., CapellaG.: Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences.Int. J. Cancer, 57: 167–171, 1994.
34.
SidneyJ., GreyH.M., KuboR.T., SetteA.: Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs.Immunol. Today, 17: 261–266, 1996.
35.
SteinleA., SchendelD.J.: HLA class I alleles of LCL 721 and 174xCEM.T2 (T2).Tissue Antigens, 44: 268–270, 1994.
36.
StuberG., LederG.H., StorkusW.I., LotzeM.T., ModrowS., SzékelyL., WolfH., KleinE., KarreK., KleinG.: Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.Eur. J. Immunol., 24: 765–768, 1994.
37.
Ten BoschG.J.A., JoostenA.M., KesslerJ.H., MeliefC.J.M., LeeksmaO.C.: Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.Blood, 88: 3522–3527, 1996.
38.
Van ElsasA., NumanH.W., Van der MinneC.E., MourerJ.S., KastW.M., MeliefC.J.M., SchrierP.I.: Induction and characterization of cytotoxic T-lymphocytes recognizing p21RAS peptide presented by HLA-A*0201.Int. J. Cancer, 61: 389–396, 1995.
39.
ZoubekA., PfleidererC., Salzer-KuntschikM., AmannG., WindhagerR., FinkF.M., KoscielniakE., DelattreO., StrehlS., AmbrosP.F., GadnerH., KovarH.: Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data.Br. J. Cancer, 70: 908–913, 1994.
40.
ZucmanJ., MelotT., DesmazeC., GhysdaelJ., PlougastelB., PeterM., ZuckerJ.M., TricheT.J., SheerD., Turc-CarelC., AmbrosP., CombaretV., LenoirG., AuriasA., ThomasG., DelattreO.: Combinatorial generation of variable fusion proteins in the Ewing family of tumours.Embo J.:12, 4481–4487, 1993.
